The manufacturer of escitalopram (Cipralex®) oral drops has written to healthcare professionals to advise that the 10mg/ml formulation will be discontinued with effect from 31st March 2011. The 20mg/ml formulation will continue to be available.
This decision is the result of a rationalisation of the manufacturing process but will also eliminate the potential for confusion and dosing errors presented by the two current strengths. Patients currently taking the 10mg/ml product can be switched to the 20mg/ml product without any need for cross tapering by halving the dose volume administered.
Action: Clinicians should be aware of the discontinuation of this product. Patients who are affected should be identified and changed to a suitable alternative.
|« NICE Guidance - February 2011||Script charge increase for 2011 »|